Studies also prove that CD338+/ABCG2+ cells have an adaptive advantage in vivo over the differentiated bulk of cancer cells [23], and notably both ABCG2+ and ABCG2− cell subpopulations were observed to display similar tumorigenic potential [24]. Here, ABCG2 is linked to cancer.